BACKGROUND: Deep venous thrombosis (DVT) and pulmonary embolism (PE) are possible sources of morbidity and mortality in patients with musculoskeletal neoplasms (MSN). OBJECTIVE: To compare the efficacy of aspirin (ASA) and pneumatic compression devices (PCD) to low-molecular-weight heparin (LMWH) and PCD in patients undergoing orthopedic procedures for MSN of the pelvis or lower extremity. METHODS: Of 348 patients who met the study criteria, 195 were treated with ASA/PCD and 153 with LMWH/PCD. There were 18 DVT including 8 in ASA/PCD group and 10 in LMWH/PCD group. There were four PEs, all in the LMWH/PCD group. RESULTS: We found no significant difference in DVT rate between ASA/PCD and LMWH/PCD when used for prophylaxis against thromboembolic complications. Our analysis shows that procedures of the thigh, soft tissue resections, and malignant disease were more often managed with ASA/PCD while joint arthroplasty, procedures of the hip/pelvis, and metastatic disease were more often managed with LMWH/PCD. CONCLUSION: DVT prophylaxis in orthopedic oncology remains a complex topic in which physicians must balance the risks of thromboembolic disease against the risks of post-operative complications. 2010 Wiley-Liss, Inc.
BACKGROUND: Deep venous thrombosis (DVT) and pulmonary embolism (PE) are possible sources of morbidity and mortality in patients with musculoskeletal neoplasms (MSN). OBJECTIVE: To compare the efficacy of aspirin (ASA) and pneumatic compression devices (PCD) to low-molecular-weight heparin (LMWH) and PCD in patients undergoing orthopedic procedures for MSN of the pelvis or lower extremity. METHODS: Of 348 patients who met the study criteria, 195 were treated with ASA/PCD and 153 with LMWH/PCD. There were 18 DVT including 8 in ASA/PCD group and 10 in LMWH/PCD group. There were four PEs, all in the LMWH/PCD group. RESULTS: We found no significant difference in DVT rate between ASA/PCD and LMWH/PCD when used for prophylaxis against thromboembolic complications. Our analysis shows that procedures of the thigh, soft tissue resections, and malignant disease were more often managed with ASA/PCD while joint arthroplasty, procedures of the hip/pelvis, and metastatic disease were more often managed with LMWH/PCD. CONCLUSION: DVT prophylaxis in orthopedic oncology remains a complex topic in which physicians must balance the risks of thromboembolic disease against the risks of post-operative complications. 2010 Wiley-Liss, Inc.
Authors: Olivier Q Groot; Paul T Ogink; Nuno Rei Paulino Pereira; Marco L Ferrone; Mitchell B Harris; Santiago A Lozano-Calderon; Andrew J Schoenfeld; Joseph H Schwab Journal: Clin Orthop Relat Res Date: 2019-07 Impact factor: 4.176
Authors: Olivier Q Groot; Paul T Ogink; Stein J Janssen; Nuno Rui Paulino Pereira; Santiago Lozano-Calderon; Kevin Raskin; Francis Hornicek; Joseph H Schwab Journal: Clin Orthop Relat Res Date: 2018-10 Impact factor: 4.176
Authors: Stavros Kakkos; George Kirkilesis; Joseph A Caprini; George Geroulakos; Andrew Nicolaides; Gerard Stansby; Daniel J Reddy Journal: Cochrane Database Syst Rev Date: 2022-01-28
Authors: Stavros K Kakkos; Joseph A Caprini; George Geroulakos; Andrew N Nicolaides; Gerard Stansby; Daniel J Reddy; Ioannis Ntouvas Journal: Cochrane Database Syst Rev Date: 2016-09-07